Opus Genetics, Inc. Stock Issued During Period, Value, Issued for Services
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Opus Genetics, Inc. stock issued during period, value, issued for services for the quarter ending 2018-12-31 was $0.00.
- Opus Genetics, Inc. stock issued during period, value, issued for services for the quarter ending 2018-09-30 was $10.50K, a 43.09% decline year-over-year.
- Opus Genetics, Inc. stock issued during period, value, issued for services for the quarter ending 2018-06-30 was $0.00.
- Opus Genetics, Inc. stock issued during period, value, issued for services for the quarter ending 2018-03-31 was $12.15K, a 4.71% decline year-over-year.
- Opus Genetics, Inc. stock issued during period, value, issued for services for fiscal 2018 was $22.65K, a 27.40% decline from fiscal 2017.
- Opus Genetics, Inc. stock issued during period, value, issued for services for fiscal 2017 was $31.20K, a 68.05% decline from fiscal 2016.
- Opus Genetics, Inc. stock issued during period, value, issued for services for fiscal 2016 was $97.65K, a 4.27% decline from fiscal 2015.
- Opus Genetics, Inc. stock issued during period, value, issued for services for fiscal 2015 was $102.00K, a 75.06% decline from fiscal 2014.
| Period end | Stock Issued During Period, Value, Issued for Services 3 month | Stock Issued During Period, Value, Issued for Services 12 month |
|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $22.65K 10-K · filed 2020-02-21 |
| 2018-09-30 | $10.50K 10-Q · filed 2019-11-06 | $22.65K derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $30.60K derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | $12.15K 10-Q · filed 2019-05-10 | $30.60K derived: sum of 4 quarters · filed 2019-05-10 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $31.20K 10-K · filed 2019-03-07 |
| 2017-09-30 | $18.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $31.20K derived: sum of 4 quarters · filed 2018-03-09 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $45.45K derived: sum of 4 quarters · filed 2018-03-09 |
| 2017-03-31 | $12.75K 10-Q · filed 2017-05-03 | $61.65K derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $97.65K 10-K · filed 2018-03-09 |
| 2016-09-30 | $32.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | |
| 2016-06-30 | $16.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | |
| 2016-03-31 | $48.75K 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $102.00K 10-K · filed 2018-03-09 | |
| 2014-12-31 | $409.00K 10-K · filed 2017-02-24 | |
| 2013-12-31 | $306.80K 10-K · filed 2016-03-14 | |
| 2010-12-31 | $2.11M 10-K · filed 2014-03-21 | |
| 2005-12-31 | $21.88K 10-K · filed 2014-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |